AM

Amicogen, Inc.

Industrial biotechnology company specializing in specialty enzymes and proteins.

092040 | KO

Overview

Corporate Details

ISIN(s):
KR7092040005
LEI:
Country:
South Korea
Address:
경상남도 진주시 문산읍 월아산로950번길 14-10 아미코젠 문산 1공장, 진주시

Description

Amicogen, Inc. is an industrial biotechnology company specializing in the development and production of specialty enzymes and proteins. The company operates across three primary business areas: Enzyme and Biopharmaceuticals, Healthcare and Nutrition, and Bioprocess and CDMO (Contract Development and Manufacturing Organization) services. Leveraging its proprietary enzyme technology, Amicogen creates innovative solutions for the biopharmaceutical, food, and cosmetics industries. The healthcare division develops and manufactures functional food ingredients and nutritional products. The company also provides bioprocess solutions, including protein purification resins and comprehensive CDMO services to support the biopharmaceutical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2026-01-06 00:00
[기재정정]증권신고서(지분증권)
Korean 4.2 MB
2025-12-30 00:00
[기재정정]전환가액의조정 (제5회차)
Korean 14.3 KB
2025-12-29 00:00
전환가액의조정 (제5회차)
Korean 11.3 KB
2025-12-19 00:00
주요사항보고서(유상증자결정)
Korean 25.2 KB
2025-12-19 00:00
증권신고서(지분증권)
Korean 2.9 MB
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-09-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-18 00:00
전환가액의조정 (제4회차)
Korean 10.6 KB
2025-09-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
불성실공시법인지정 (공시변경)
Korean 6.0 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 2.3 MB
2025-08-11 00:00
증권발행결과(자율공시) (제6회차 CB)
Korean 5.6 KB
2025-08-01 00:00
주요사항보고서(전환사채권발행결정)
Korean 49.8 KB
2025-07-30 00:00
소송등의판결ㆍ결정(일정금액이상의청구) (대여금 청구-취하)
Korean 7.0 KB
2025-07-28 00:00
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.3 KB

Automate Your Workflow. Get a real-time feed of all Amicogen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amicogen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amicogen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.